MXPA04009692A - Composiciones y metodos para dosificar liposomas de ciertos tamanos para tratar o prevenir enfermedad. - Google Patents

Composiciones y metodos para dosificar liposomas de ciertos tamanos para tratar o prevenir enfermedad.

Info

Publication number
MXPA04009692A
MXPA04009692A MXPA04009692A MXPA04009692A MXPA04009692A MX PA04009692 A MXPA04009692 A MX PA04009692A MX PA04009692 A MXPA04009692 A MX PA04009692A MX PA04009692 A MXPA04009692 A MX PA04009692A MX PA04009692 A MXPA04009692 A MX PA04009692A
Authority
MX
Mexico
Prior art keywords
liposomes
treat
methods
dosing
compositions
Prior art date
Application number
MXPA04009692A
Other languages
English (en)
Spanish (es)
Inventor
Wendi V Rodrigueza
Original Assignee
Esperion Luv Dev Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Luv Dev Inc filed Critical Esperion Luv Dev Inc
Publication of MXPA04009692A publication Critical patent/MXPA04009692A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
MXPA04009692A 2002-04-05 2003-04-04 Composiciones y metodos para dosificar liposomas de ciertos tamanos para tratar o prevenir enfermedad. MXPA04009692A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37040902P 2002-04-05 2002-04-05
PCT/US2003/010339 WO2003086351A1 (en) 2002-04-05 2003-04-04 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease

Publications (1)

Publication Number Publication Date
MXPA04009692A true MXPA04009692A (es) 2006-03-08

Family

ID=29250522

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04009692A MXPA04009692A (es) 2002-04-05 2003-04-04 Composiciones y metodos para dosificar liposomas de ciertos tamanos para tratar o prevenir enfermedad.

Country Status (26)

Country Link
US (2) US20040009216A1 (enExample)
EP (1) EP1501482A1 (enExample)
JP (1) JP2005527582A (enExample)
KR (1) KR20050009988A (enExample)
CN (1) CN1655764A (enExample)
AP (1) AP2004003157A0 (enExample)
AU (1) AU2003230800A1 (enExample)
BR (1) BR0309030A (enExample)
CA (1) CA2480763A1 (enExample)
CR (1) CR7563A (enExample)
EA (1) EA007986B1 (enExample)
EC (1) ECSP045409A (enExample)
HR (1) HRP20040915A2 (enExample)
IL (1) IL164370A0 (enExample)
IS (1) IS7493A (enExample)
MA (1) MA27298A1 (enExample)
MX (1) MXPA04009692A (enExample)
NO (1) NO20044751L (enExample)
NZ (1) NZ535900A (enExample)
OA (1) OA12799A (enExample)
PL (1) PL372689A1 (enExample)
RS (1) RS87704A (enExample)
TN (1) TNSN04190A1 (enExample)
UA (1) UA80121C2 (enExample)
WO (1) WO2003086351A1 (enExample)
ZA (1) ZA200407947B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037271A1 (en) * 2002-10-25 2004-05-06 Vasogen Ireland Limited Cyclooxygenase regulation with ps liposomes
AU2003275842A1 (en) * 2002-10-25 2004-05-13 Vasogen Ireland Limited Cyclooxygenase regulation with pg liposomes
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
MXPA06000805A (es) * 2003-07-21 2006-04-18 Vasogen Ireland Ltd Liposomas que contienen grupos de glicerol fosfato para tratar una condicion inflamatoria aguda.
US20080260861A1 (en) * 2004-04-07 2008-10-23 The General Hospital Corporation Modulating Lymphatic Function
JP2008521818A (ja) * 2004-11-23 2008-06-26 メデイカル・カレツジ・オブ・ジヨージア ケラチノサイト機能を調節するための方法および組成物
KR100891595B1 (ko) * 2005-02-28 2009-04-03 주식회사 케이티앤지 혈액 단백질의 삼출을 감소시키는 조성물
KR100768265B1 (ko) * 2005-11-10 2007-10-17 한국화학연구원 혈액내 순환시간을 향상시키기 위한 헤파린이 수식된리포솜 및 이의 제조방법
JP4395658B2 (ja) * 2005-11-17 2010-01-13 エムジーファーマ株式会社 コレステロール再上昇抑制用組成物およびその用法
US8697120B2 (en) * 2006-05-01 2014-04-15 Johns Hopkins University Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
ES2874149T3 (es) * 2006-05-11 2021-11-04 Alnylam Pharmaceuticals Inc Composiciones y métodos para inhibir la expresión del gen PCSK9
EP2245039A4 (en) * 2008-01-31 2012-06-06 Alnylam Pharmaceuticals Inc OPTIMIZED METHODS FOR EXPORING DSRNA TO TARGET THE PCSK9 GEN
US20100267806A1 (en) * 2009-03-12 2010-10-21 David Bumcrot LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
KR102229618B1 (ko) 2009-05-05 2021-03-18 알닐람 파마슈티칼스 인코포레이티드 지질 조성물
WO2010140061A2 (en) * 2009-06-03 2010-12-09 John Charles Mayo Formulations for the treatment of deep tissue pain
NZ622843A (en) * 2009-06-10 2015-10-30 Tekmira Pharmaceuticals Corp Improved lipid formulation
WO2010147992A1 (en) 2009-06-15 2010-12-23 Alnylam Pharmaceuticals, Inc. Methods for increasing efficacy of lipid formulated sirna
NZ597504A (en) * 2009-06-15 2013-10-25 Alnylam Pharmaceuticals Inc Lipid formulated dsrna targeting the pcsk9 gene
WO2011059262A2 (ko) * 2009-11-13 2011-05-19 경북대학교 산학협력단 사멸세포 표적 펩타이드, 표지물질 및 치료제를 포함하는 리포솜의 아포토시스 관련 질환의 예방, 치료 또는 치료진단을 위한 용도
CN108114285A (zh) 2011-07-15 2018-06-05 纽斯尔特科学公司 用于调节代谢途径的组合物和方法
CN104918610B (zh) 2012-11-13 2018-04-10 纽斯尔特科学公司 用于增强能量代谢的组合物和方法
PT2929031T (pt) 2012-12-05 2018-01-19 Alnylam Pharmaceuticals Inc Composições de irna de pcsk9 e métodos de seu uso
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
CN104422750B (zh) * 2013-09-05 2016-02-10 中国科学院大连化学物理研究所 一种烟叶中磷脂酰乙醇胺与甘油三酯含量的检测方法
WO2015108134A1 (ja) * 2014-01-17 2015-07-23 株式会社西崎創薬研究所 Ｇｌｕｔ４エンドサイトーシス抑制剤
CN110279654B (zh) * 2019-07-22 2023-02-03 苏州大学附属第一医院 缓释阿司匹林脂质体水凝胶、制备方法及其在制备治疗复发性腰椎间盘突出症药物中的应用
WO2022118913A1 (ja) * 2020-12-04 2022-06-09 株式会社レグイミューン 体内動態が改善されたＣＤ１ｄリガンド化合物含有リポソーム製剤
US12133966B2 (en) 2020-12-22 2024-11-05 Regina E. HERZLINGER Methods, systems, and apparatus for administering an antibody treatment via infusion
US11806507B2 (en) 2020-12-22 2023-11-07 Regina E. HERZLINGER Methods, systems, and apparatus for administering an antibody treatment via infusion
AU2021409558A1 (en) * 2020-12-22 2023-07-20 Regina E. HERZLINGER Methods, systems, and apparatus for administering a monoclonal and/or polyclonal antibody treatment via rapid infusion
WO2025159416A1 (ko) * 2024-01-22 2025-07-31 연세대학교 산학협력단 단핵구에 탑재되는 리포좀을 포함하는 약물 전달체

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
JPS5348976A (en) * 1976-10-18 1978-05-02 Nippon Zeon Co Ltd Mass transfer apparatus of hollow fiber type
US4186183A (en) * 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4247393A (en) * 1979-01-11 1981-01-27 Wallace Richard A Hemodialysis assist device
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
DE3276390D1 (en) * 1981-09-10 1987-06-25 Intermedicat Gmbh Method for the selective extracorporeal precipitation of low-density lipoproteins from serum or plasma
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4532089A (en) * 1984-01-14 1985-07-30 Northwestern University Method of preparing giant size liposomes
US4663167A (en) * 1984-04-16 1987-05-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment of disseminated fungal infections in mammals
US4978654A (en) * 1984-04-16 1990-12-18 Board Of Regents, The University Of Texas System Composition and method for treatment of disseminated fungal infections in mammals
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
ATE78158T1 (de) * 1985-05-22 1992-08-15 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
US4774085A (en) * 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4812314A (en) * 1986-02-24 1989-03-14 Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization Lipid replacement therapy
US5204112A (en) * 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
US5252263A (en) * 1986-06-16 1993-10-12 The Liposome Company, Inc. Induction of asymmetry in vesicles
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US5258499A (en) * 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5219994A (en) * 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
US5015483A (en) * 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
DK0469082T3 (da) * 1989-04-18 1995-08-28 Nexstar Pharmaceuticals Inc Liposomal målretning mod iskæmiske væv
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE4018767A1 (de) * 1990-06-12 1991-12-19 Braun Melsungen Ag Wirkstofffreie liposomen zur behandlung von atherosklerose
US5231090A (en) * 1990-07-30 1993-07-27 University Of Miami Treatment for hypercholesterolemia
US5556637A (en) * 1990-08-06 1996-09-17 A. Nattermann & Cie. Gmbh Water containing liposome system
JPH04305879A (ja) * 1990-09-12 1992-10-28 Fuji Electric Co Ltd ディスク記憶装置のヘッド操作用可動体の拘束装置
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5405832A (en) * 1991-11-27 1995-04-11 Immtech International Inc. Method of treating non-streptococcal bacterial infections
US5219888A (en) * 1992-03-31 1993-06-15 American Cyanamid Company Use of retinoids for the treatment of coronary artery disease
US5250060A (en) * 1992-06-26 1993-10-05 Carbo Paul L Angioplasty apparatus
US5637315A (en) * 1993-01-04 1997-06-10 Thomas Jefferson University Treatment of disease states induced by oxidative stress
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6773719B2 (en) * 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US6139871A (en) * 1995-07-26 2000-10-31 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US6312719B1 (en) * 1994-03-04 2001-11-06 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US5746223A (en) * 1996-10-11 1998-05-05 Williams; Kevin Jon Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis
US5599306A (en) * 1994-04-01 1997-02-04 Localmed, Inc. Method and apparatus for providing external perfusion lumens on balloon catheters
US5622715A (en) * 1994-06-10 1997-04-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of improving renal function
US5753613A (en) * 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5674488A (en) * 1994-10-07 1997-10-07 Reich; John J. Method for prevention and treatment of hyperchlolesterolemia by in vivo hydrogenation of cholesterol
CA2206289A1 (en) * 1994-11-23 1996-05-30 Kimberly-Clark Worldwide, Inc. Absorbent article having a composite absorbent core
US5489611A (en) * 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5741514A (en) * 1995-08-31 1998-04-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for reducing serum lipoprotein(a) concentration
AU759964B2 (en) * 1995-10-11 2003-05-01 Esperion Luv Development, Inc. Liposomal compositions and methods of using them
US5846691A (en) * 1996-07-08 1998-12-08 Polyfibron Technologies, Inc. Composite relief image printing plates and methods for preparing same
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
CN1329359C (zh) * 1999-04-01 2007-08-01 埃斯佩里安医疗公司 醚化合物,及其组合物和用途
WO2000069412A1 (en) * 1999-05-14 2000-11-23 Esperion Luv Development, Inc. Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto
BR0212866A (pt) * 2001-09-28 2004-09-14 Esperion Therapeutics Inc Métodos de produzir uma suspensão de vesìcula e lipossomas e dispositivo para extrudar uma suspensão aquosa de lipìdeos a alta pressão

Also Published As

Publication number Publication date
MA27298A1 (fr) 2005-05-02
KR20050009988A (ko) 2005-01-26
OA12799A (en) 2006-07-11
JP2005527582A (ja) 2005-09-15
BR0309030A (pt) 2005-02-01
NZ535900A (en) 2008-08-29
EA007986B1 (ru) 2007-02-27
CR7563A (es) 2005-09-20
TNSN04190A1 (en) 2007-03-12
US20080213351A1 (en) 2008-09-04
AP2004003157A0 (en) 2004-12-31
UA80121C2 (en) 2007-08-27
HRP20040915A2 (en) 2005-02-28
NO20044751L (no) 2004-12-20
IL164370A0 (en) 2005-12-18
WO2003086351A1 (en) 2003-10-23
PL372689A1 (en) 2005-07-25
EA200401317A1 (ru) 2005-06-30
EP1501482A1 (en) 2005-02-02
ZA200407947B (en) 2006-07-26
CA2480763A1 (en) 2003-10-23
RS87704A (sr) 2006-12-15
CN1655764A (zh) 2005-08-17
AU2003230800A1 (en) 2003-10-27
US20040009216A1 (en) 2004-01-15
ECSP045409A (es) 2005-03-10
IS7493A (is) 2004-10-08

Similar Documents

Publication Publication Date Title
AP2004003157A0 (en) Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
WO2005043971A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
IL136839A0 (en) Pharmaceutical compositions comprising cannabidiol derivatives
IL171683A (en) Immunosuppressive Compounds, Medicinal Products Containing Them and Their Use in the Preparation of Medication for Treatment
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
IL176449A0 (en) Generally linear effervescent oral fentanyl dosage form and methods of administering
AU2001283563A1 (en) Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
HUP0402661A3 (en) Formulation and dosage form for the controlled delivery of therapeutic agents
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
SG149054A1 (en) Multiparticulate formulations for oral delivery
WO2004037207A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
GB0201367D0 (en) Composition
WO2005094899A8 (en) Clusterin antisense therapy for treatment of cancer
GB0328180D0 (en) Combination
WO2005039497A3 (en) Methods and compositions comprising thalidomide for treatment of fibromyalgia
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
EP1583545A4 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF PEPTIDES OF HIV GP41 AND ITS THERAPEUTIC USE
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
WO2004041181A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
IL151627A0 (en) Divided dose therapies with vascular damaging activity
MXPA05009849A (es) Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2.
MXPA04009396A (es) Combinacion que comprende un inhibidor cdk y doxorubicina.
AU2003266065A1 (en) Method of preparing pharmaceutical dosage forms containing multiple active ingredients